中国药物警戒
中國藥物警戒
중국약물경계
CHINESE JOURNAL OF PHARMACOVIGILANCE
2014年
10期
628-631
,共4页
程茂波%史新立%苗晶晶%刘威%聂飞龙
程茂波%史新立%苗晶晶%劉威%聶飛龍
정무파%사신립%묘정정%류위%섭비룡
经导管植入式主动脉人工心脏瓣膜%临床试验%可行性研究%确证性研究
經導管植入式主動脈人工心髒瓣膜%臨床試驗%可行性研究%確證性研究
경도관식입식주동맥인공심장판막%림상시험%가행성연구%학증성연구
transcatheter aortic valve implantation%clinical trial%feasibility study%pivotal study
用于治疗有症状的重度主动脉瓣狭窄的经导管植入式主动脉人工心脏瓣膜的研发日益增多,但并未有规范性临床试验指导意见,缺少安全性和有效性评价的统一原则,为了更好地引导研究者完成上市前临床试验研究,通过结合该类产品已完成的临床试验研究情况、心脏病治疗指南及国内心血管内科、心血管外科和临床统计学专家的意见,总结了目前对于该类产品临床试验的初步建议。在中国境内开展临床试验时,建议首先完成可行性研究;确证性研究按照产品应用人群风险收益分析,分别对开展安全性和有效性评价,建议优先选择不适合常规外科手术有症状的重度主动脉瓣狭窄患者作为受试人群。
用于治療有癥狀的重度主動脈瓣狹窄的經導管植入式主動脈人工心髒瓣膜的研髮日益增多,但併未有規範性臨床試驗指導意見,缺少安全性和有效性評價的統一原則,為瞭更好地引導研究者完成上市前臨床試驗研究,通過結閤該類產品已完成的臨床試驗研究情況、心髒病治療指南及國內心血管內科、心血管外科和臨床統計學專傢的意見,總結瞭目前對于該類產品臨床試驗的初步建議。在中國境內開展臨床試驗時,建議首先完成可行性研究;確證性研究按照產品應用人群風險收益分析,分彆對開展安全性和有效性評價,建議優先選擇不適閤常規外科手術有癥狀的重度主動脈瓣狹窄患者作為受試人群。
용우치료유증상적중도주동맥판협착적경도관식입식주동맥인공심장판막적연발일익증다,단병미유규범성림상시험지도의견,결소안전성화유효성평개적통일원칙,위료경호지인도연구자완성상시전림상시험연구,통과결합해류산품이완성적림상시험연구정황、심장병치료지남급국내심혈관내과、심혈관외과화림상통계학전가적의견,총결료목전대우해류산품림상시험적초보건의。재중국경내개전림상시험시,건의수선완성가행성연구;학증성연구안조산품응용인군풍험수익분석,분별대개전안전성화유효성평개,건의우선선택불괄합상규외과수술유증상적중도주동맥판협착환자작위수시인군。
Transcatheter aortic valve implantation for the patients suffering from severe aortic stenosis has emerged as a promising technique alternative to conventional surgical aortic valve replacement, the guidances of clinical study to evaluate the safety and efficacy of the products have not been drafted as so far. The recommendations which were drafted according to the existing clinical data and guideline for valvular heart disease and expert advice were intro duced in the article in order to provide a guidance to manufacturers. Feasibility study to see if a larger pivotal study is practical and to refine the study protocol for the pivotal study was recommended firstly, the hypothesis of pivotal study was built in accordance with benefit-risk analysis, the aortic stenosis patients who cannot undergo surgery was preferen-tially treated in clinical trial.